In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing ΔF08-CFTR

Ronald C. Rubenstein, Marie E. Egan, Pamela L. Zeitlin

Research output: Contribution to journalArticle

Abstract

The most common cystic fibrosis transmembrane conductance regulator mutation, ΔF508-CFTR, is a partially functional chloride channel that is retained in the endoplasmic reticulum and degraded. We hypothesize that a known transcriptional regulator, sodium 4-phenylbutyrate (4PBA), will enable a greater fraction of ΔF508-CFTR to escape degradation and appear at the cell surface. Primary cultures of nasal polyp epithelia from CF patients (ΔF508 homozygous or heterozygous), or the CF bronchial epithelial cell line IB3-1 (ΔF508/W1282X) were exposed to 4PBA for up to 7 d in culture. 4PBA treatment at concentrations of 0.1 and 2 mM resulted in the restoration of forskolin-activated chloride secretion. Protein kinase A-activated, linear, 10 pS chloride channels appeared at the plasma membrane of IB3-1 cells at the tested concentration of 2.5 mM. Treatment of IB3-1 cells with 0.1-1 mM 4PBA and primary nasal epithelia with 5 mM 4PBA also resulted in the appearance of higher molecular mass forms of CFTR consistent with addition and modification of oligosaccharides in the Golgi apparatus, as detected by immunoblotting of whole cell lysates with anti-CFTR antisera. Immunocytochemistry in CF epithelial cells treated with 4PBA was consistent with increasing amounts of ΔF508-CFTR. These data indicate that 4PBA is a promising pharmacologic agent for inducing correction of the CF phenotype in CF patients carrying the ΔF508 mutation.

Original languageEnglish (US)
Pages (from-to)2457-2465
Number of pages9
JournalJournal of Clinical Investigation
Volume100
Issue number10
StatePublished - Nov 15 1997

Fingerprint

Cystic Fibrosis
Chlorides
Epithelial Cells
Chloride Channels
Nasal Mucosa
Nasal Polyps
Cystic Fibrosis Transmembrane Conductance Regulator
Mutation
Golgi Apparatus
Colforsin
Cyclic AMP-Dependent Protein Kinases
In Vitro Techniques
4-phenylbutyric acid
Oligosaccharides
Immunoblotting
Endoplasmic Reticulum
Immune Sera
Immunohistochemistry
Cell Membrane
Phenotype

Keywords

  • CFTR
  • Cystic fibrosis
  • Pharmacotherapy
  • Phenylbutyrate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing ΔF08-CFTR. / Rubenstein, Ronald C.; Egan, Marie E.; Zeitlin, Pamela L.

In: Journal of Clinical Investigation, Vol. 100, No. 10, 15.11.1997, p. 2457-2465.

Research output: Contribution to journalArticle

@article{6cc8420f623b4a3e88ff540d0e32fde4,
title = "In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing ΔF08-CFTR",
abstract = "The most common cystic fibrosis transmembrane conductance regulator mutation, ΔF508-CFTR, is a partially functional chloride channel that is retained in the endoplasmic reticulum and degraded. We hypothesize that a known transcriptional regulator, sodium 4-phenylbutyrate (4PBA), will enable a greater fraction of ΔF508-CFTR to escape degradation and appear at the cell surface. Primary cultures of nasal polyp epithelia from CF patients (ΔF508 homozygous or heterozygous), or the CF bronchial epithelial cell line IB3-1 (ΔF508/W1282X) were exposed to 4PBA for up to 7 d in culture. 4PBA treatment at concentrations of 0.1 and 2 mM resulted in the restoration of forskolin-activated chloride secretion. Protein kinase A-activated, linear, 10 pS chloride channels appeared at the plasma membrane of IB3-1 cells at the tested concentration of 2.5 mM. Treatment of IB3-1 cells with 0.1-1 mM 4PBA and primary nasal epithelia with 5 mM 4PBA also resulted in the appearance of higher molecular mass forms of CFTR consistent with addition and modification of oligosaccharides in the Golgi apparatus, as detected by immunoblotting of whole cell lysates with anti-CFTR antisera. Immunocytochemistry in CF epithelial cells treated with 4PBA was consistent with increasing amounts of ΔF508-CFTR. These data indicate that 4PBA is a promising pharmacologic agent for inducing correction of the CF phenotype in CF patients carrying the ΔF508 mutation.",
keywords = "CFTR, Cystic fibrosis, Pharmacotherapy, Phenylbutyrate",
author = "Rubenstein, {Ronald C.} and Egan, {Marie E.} and Zeitlin, {Pamela L.}",
year = "1997",
month = "11",
day = "15",
language = "English (US)",
volume = "100",
pages = "2457--2465",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "10",

}

TY - JOUR

T1 - In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing ΔF08-CFTR

AU - Rubenstein, Ronald C.

AU - Egan, Marie E.

AU - Zeitlin, Pamela L.

PY - 1997/11/15

Y1 - 1997/11/15

N2 - The most common cystic fibrosis transmembrane conductance regulator mutation, ΔF508-CFTR, is a partially functional chloride channel that is retained in the endoplasmic reticulum and degraded. We hypothesize that a known transcriptional regulator, sodium 4-phenylbutyrate (4PBA), will enable a greater fraction of ΔF508-CFTR to escape degradation and appear at the cell surface. Primary cultures of nasal polyp epithelia from CF patients (ΔF508 homozygous or heterozygous), or the CF bronchial epithelial cell line IB3-1 (ΔF508/W1282X) were exposed to 4PBA for up to 7 d in culture. 4PBA treatment at concentrations of 0.1 and 2 mM resulted in the restoration of forskolin-activated chloride secretion. Protein kinase A-activated, linear, 10 pS chloride channels appeared at the plasma membrane of IB3-1 cells at the tested concentration of 2.5 mM. Treatment of IB3-1 cells with 0.1-1 mM 4PBA and primary nasal epithelia with 5 mM 4PBA also resulted in the appearance of higher molecular mass forms of CFTR consistent with addition and modification of oligosaccharides in the Golgi apparatus, as detected by immunoblotting of whole cell lysates with anti-CFTR antisera. Immunocytochemistry in CF epithelial cells treated with 4PBA was consistent with increasing amounts of ΔF508-CFTR. These data indicate that 4PBA is a promising pharmacologic agent for inducing correction of the CF phenotype in CF patients carrying the ΔF508 mutation.

AB - The most common cystic fibrosis transmembrane conductance regulator mutation, ΔF508-CFTR, is a partially functional chloride channel that is retained in the endoplasmic reticulum and degraded. We hypothesize that a known transcriptional regulator, sodium 4-phenylbutyrate (4PBA), will enable a greater fraction of ΔF508-CFTR to escape degradation and appear at the cell surface. Primary cultures of nasal polyp epithelia from CF patients (ΔF508 homozygous or heterozygous), or the CF bronchial epithelial cell line IB3-1 (ΔF508/W1282X) were exposed to 4PBA for up to 7 d in culture. 4PBA treatment at concentrations of 0.1 and 2 mM resulted in the restoration of forskolin-activated chloride secretion. Protein kinase A-activated, linear, 10 pS chloride channels appeared at the plasma membrane of IB3-1 cells at the tested concentration of 2.5 mM. Treatment of IB3-1 cells with 0.1-1 mM 4PBA and primary nasal epithelia with 5 mM 4PBA also resulted in the appearance of higher molecular mass forms of CFTR consistent with addition and modification of oligosaccharides in the Golgi apparatus, as detected by immunoblotting of whole cell lysates with anti-CFTR antisera. Immunocytochemistry in CF epithelial cells treated with 4PBA was consistent with increasing amounts of ΔF508-CFTR. These data indicate that 4PBA is a promising pharmacologic agent for inducing correction of the CF phenotype in CF patients carrying the ΔF508 mutation.

KW - CFTR

KW - Cystic fibrosis

KW - Pharmacotherapy

KW - Phenylbutyrate

UR - http://www.scopus.com/inward/record.url?scp=0030809817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030809817&partnerID=8YFLogxK

M3 - Article

C2 - 9366560

AN - SCOPUS:0030809817

VL - 100

SP - 2457

EP - 2465

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 10

ER -